Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Short-term Investments (2017 - 2025)

Integra Lifesciences Holdings' Short-term Investments history spans 6 years, with the latest figure at $28.7 million for Q4 2025.

  • For Q4 2025, Short-term Investments rose 5.51% year-over-year to $28.7 million; the TTM value through Dec 2025 reached $28.7 million, up 5.51%, while the annual FY2025 figure was $28.7 million, 5.51% up from the prior year.
  • Short-term Investments for Q4 2025 was $28.7 million at Integra Lifesciences Holdings, down from $35.7 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $81.7 million in Q2 2024 and bottomed at $1.1 million in Q4 2022.
  • The 4-year median for Short-term Investments is $34.2 million (2025), against an average of $38.2 million.
  • The largest annual shift saw Short-term Investments soared 2166.67% in 2024 before it crashed 56.31% in 2025.
  • A 4-year view of Short-term Investments shows it stood at $1.1 million in 2022, then grew by 9.09% to $1.2 million in 2023, then skyrocketed by 2166.67% to $27.2 million in 2024, then grew by 5.51% to $28.7 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Short-term Investments are $28.7 million (Q4 2025), $35.7 million (Q2 2025), and $34.2 million (Q1 2025).